MEOBF — MESOBLAST LTD
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1345099 ·
Last close
$1.90
Market Cap
$2.47B
52W High
$2.59
52W Low
$1.30
ADV30
33,353
Next earnings
2026-08-26
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 773,079,000 | 47,390,000 | 204,674,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | — | — | — | — | 782,307,000 | 129,573,000 | 207,623,000 |
| Sep 2025 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,051,065,000
Inventory
$21,664,000
Receivables
$43,300,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$120,250,000
EBITDA
$-44,605,000
Free Cash Flow
$-51,976,248
Enterprise Value
$2,496,031,488
Total Cash
$102,914,000
Total Debt
$127,334,000
Shares Out
1,298,548,778
Trailing EPS
$-0.04
Book Value
$0.44
ROE
-9.9%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 120,250,000 | -51,250,000 | -57,500,000 | 773,079,000 | 204,674,000 | 568,405,000 | — |
| Jun 2025 | 17,198,000 | -62,443,000 | -102,142,000 | 784,683,000 | 187,241,000 | 597,442,000 | -49,954,000 |
| Jun 2024 | 5,902,000 | -56,224,000 | -87,956,000 | 669,153,000 | 188,798,000 | 480,355,000 | -48,458,000 |
| Jun 2023 | 7,501,000 | -69,289,000 | -81,889,000 | 669,415,000 | 167,577,000 | 501,838,000 | -63,269,000 |
| Jun 2022 | — | — | — | — | — | — | -65,782,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc. | $2.51B | $24.27 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.20B | $8.59 | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.10B | $9.38 | — |
| ALVO | Alvotech | $2.05B | $5.75 | — |
| VCEL | Vericel Corp | $2.03B | $39.71 | — |
News headlines (Yahoo Finance, 1h cache)
3 Australian Growth Stocks With Earnings Growth Up To 65%
2026-09-27 04:14 · Yahoo
Elite Australian Owner Operator Stocks To Own In September 2026
2026-09-25 11:11 · Yahoo
Sector Update: Healthcare Stocks Advance Late Afternoon
2026-09-24 20:01 · Yahoo
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
2026-09-24 11:00 · Yahoo
Mesoblast Reports Substantial Revenue Growth to US$120M
2026-08-27 00:32 · Yahoo
Mesoblast H2 Earnings Call Highlights
2026-08-27 00:02 · Yahoo
3 Australian Growth Stocks With Strong Balance Sheets In A Rate Hike Debate
2026-08-26 16:21 · Yahoo
Mesoblast Financial Results and Corporate Update Webcast
2026-08-24 11:00 · Yahoo
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
2026-08-18 15:46 · Yahoo
Sector Update: Healthcare Stocks Mixed Monday Afternoon
2026-08-17 17:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.